银屑病的生物治疗进展

被引:6
作者
解士海
马鹏程
机构
[1] 中国协和医科大学、中国医学科学院皮肤病研究所
[2] 中国协和医科大学、中国医学科学院皮肤病研究所 南京
[3] 南京
关键词
银屑病; 生物疗法;
D O I
暂无
中图分类号
R758.63 [牛皮癣(银屑病)];
学科分类号
100206 ;
摘要
随着对银屑病发病机制的深入研究 ,一些具有靶位特异性的生物制剂相继出现 ,并取得了可喜的治疗效果。文中对近年来用于银屑病治疗的生物制剂按直接杀伤致病T细胞、抑制T细胞活化与迁移、促使免疫偏向及阻断炎症性细胞因子活性 4个作用环节进行了粗略归类 ,并对其作用机制、临床评价及药代动力学结果进行了综述
引用
收藏
页码:78 / 81
页数:4
相关论文
共 25 条
[1]  
New developments in the treatment of psoriasis. Lebwohl M. Archives of Dermatology . 2002
[2]  
Novel therapies for psoriasis. Cather J,Menter A. American Journal of Clinical Dermatology . 2002
[3]  
Transplantation[P]. 英国专利:GB9904281D0,1999-04-21
[4]  
Transplantation[P]. 英国专利:GB9904281D0,1999-04-21
[5]  
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. Gottlieb AB,Lebwohl M,Shirin S,et al. Journal of the American Academy of Dermatology . 2000
[6]  
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Chaudhari U,Romano P,Mulcahy LD,et al. The Lancet . 2001
[7]  
The effectiveness of tumor necrosis factor alpha antibody(infliximab)in treating recalcitrant psoriasis:a report of2cases. O’Quinn RP,Miller JL. Archives of Dermatology . 2002
[8]  
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. Keane J,Gershon S,Wise RP,et al. The New England Journal of Medicine . 2001
[9]  
Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. Krueger JG,Walters IB,Miyazawa M,et al. Journal of the American Academy of Dermatology . 2000
[10]  
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. Abrams JR,Lebwohl MG,Guzzo CA,et al. The Journal of Clinical Investigation . 1999